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Abstract
Background: Osteoclasts have been strongly implicated in osteoarthritic cartilage degradation, at least indirectly via
bone resorption, and have been shown to degrade cartilage in vitro. The osteoclast resorption processes required
to degrade subchondral bone and cartilage—the remodeling of which is important in the osteoarthritic disease
process—have not been previously described, although cathepsin K has been indicated to participate. In this study
we profile osteoclast-mediated degradation of bovine knee joint compartments in a novel in vitro model using
biomarkers of extracellular matrix (ECM) degradation to assess the potential of osteoclast-derived resorption
processes to degrade different knee joint compartments.
Methods: Mature human osteoclasts were cultured on ECMs isolated from bovine knees—articular cartilage, cortical
bone, and osteochondral junction ECM (a subchondral bone-calcified cartilage mixture)—in the presence of inhibitors:
the cystein protease inhibitor E-64, the matrix metalloproteinase (MMP) inhibitor GM6001, or the vacuolar-type H+-
ATPase (V-ATPase) inhibitor diphyllin. Biomarkers of bone (calcium and C-terminal type I collagen (CTX-I)) and cartilage
(C2M) degradation were measured in the culture supernatants. Cultures without osteoclasts were used as background
samples. Background-subtracted biomarker levels were normalized to the vehicle condition and were analyzed using
analysis of variance with Tukey or Dunnett’s T3 post hoc test, as applicable.
Results: Osteochondral CTX-I release was inhibited by E-64 (19% of vehicle, p = 0.0008), GM6001 (51% of
vehicle, p = 0.013), and E-64/GM6001 combined (4% of vehicle, p = 0.0007)—similarly to bone CTX-I release.
Diphyllin also inhibited osteochondral CTX-I release (48% of vehicle, p = 0.014), albeit less than on bone (4%
of vehicle, p < 0.0001). Osteochondral C2M release was only inhibited by E-64 (49% of vehicle, p = 0.07) and
GM6001 (14% of vehicle, p = 0.006), with complete abrogation when combined (0% of vehicle, p = 0.004). Cartilage
C2M release was non-significantly inhibited by E-64 (69% of vehicle, p = 0.98) and was completely abrogated by
GM6001 (0% of vehicle, p = 0.16).
Conclusions: Our study supports that osteoclasts can resorb non-calcified and calcified cartilage independently of
acidification. We demonstrated both MMP-mediated and cysteine protease-mediated resorption of calcified cartilage.
Osteoclast functionality was highly dependent on the resorbed substrate, as different ECMs required different
osteoclast processes for degradation. Our novel culture system has potential to facilitate drug and biomarker
development aimed at rheumatic diseases, e.g. osteoarthritis, where pathological osteoclast processes in specific
joint compartments may contribute to the disease process.
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Background
Osteoclasts are bone-resorbing multinucleated cells de-
rived from hematopoietic stem cells via the monocytic
lineage upon stimulation with the cytokines macrophage
colony-stimulating factor (M-CSF) and receptor activa-
tor of nuclear factor kappa-B ligand (RANKL) [1]. Bone
is resorbed by osteoclasts through secretion of hydro-
chloric acid dissolving the inorganic matrix [2] and
proteases, mainly the cysteine protease cathepsin K [3–5]
and matrix metalloproteinases (MMPs) [6–8], degrading
the organic matrix. In addition to their well-established
role in normal bone turnover, osteoclasts play important
roles in diseases with progressive joint destruction, in par-
ticular in bone erosion in diarthrodial joints in rheumatoid
arthritis (RA) [9–13]. Their role in cartilage and subchon-
dral bone alterations in osteoarthritis (OA) is poorly
understood [14].
The osteochondral junction is a key compartment of
the joint. Consisting of non-calcified articular cartilage,
calcified cartilage and subchondral bone, the osteochon-
dral junction transforms shear stress from loading and
motion into compressive and tensile stress via undula-
tions in the extracellular matrices (ECMs) [14, 15]. Sub-
chondral bone sclerosis and changes in subchondral
bone metabolism, possibly mediated by osteoclast-
osteoblast coupling [16–18], are often amongst the first
detectable OA alterations [19]. In conjunction, increased
osteoclast activity and subchondral bone remodeling are
involved in OA development and progression [15]. Sup-
pressing bone resorption has resulted in beneficial sec-
ondary effects on cartilage health in several pre-clinical
OA studies and increased resorption has resulted in
cartilage deterioration [20], demonstrating how osteo-
clasts can contribute indirectly to cartilage health. The
differentiation, activity and survival of osteoclasts is tightly
regulated in healthy individuals [21] whereas monocytes
isolated from patients with OA exhibit increased osteo-
clastogenesis, elevated resorption, and reduced osteoclast
apoptosis [22].
The idea of osteoclasts being directly involved in OA
cartilage degradation is gaining increased attention. Hu-
man osteoclasts can degrade cartilage [23] and equine
osteoclasts are recruited to the subchondral bone in
spontaneous post-traumatic OA [24]. Furthermore, bone
marrow lesions have been shown to be associated with
the subchondral bone areas underlying articular cartilage
lesions, suggesting osteoclast-associated cartilage-bone
crosstalk [25, 26]. Resorption pits reaching from
subchondral bone into articular cartilage have been de-
scribed in OA [27], but which osteoclast-derived resorp-
tion processes that are involved in cartilage degradation
have not been investigated. Different osteoclast sub-
strates affect the possible ECM degradation products
and the phenotype of the resorbing osteoclasts [28]. This
suggests that the ECM can be a determinant of osteoclast
functionality, and hence there is a need for increased un-
derstanding of osteoclast effects on other ECMs of
relevance to joint pathology. MMPs [6, 8, 29, 30] and
cathepsin K [3, 6, 8, 31] have long been thought to de-
grade both bone and cartilage, but in addition to osteo-
clasts there are many other potential contributors to
MMP [32–34] and cathepsin K [34, 35] levels in the OA
joint. Therefore, the contribution of proteases specifically
derived from osteoclasts to degrading these ECMs re-
quires further investigation.
To this date direct osteoclast-derived effects and the
osteoclast processes involved in degrading the articular
cartilage and the osteochondral junction compartments
have not been determined. To shed light on if and how
osteoclasts play a role in the degradation of the different
joint components, in this study we investigated matrix-
dependent and enzyme-dependent degradation processes
by human osteoclasts on bovine joint tissues. To this end
we exploited a novel cell culture model of osteoclast-
derived bovine knee joint degradation, using osteochon-
dral ECM (a subchondral bone-calcified cartilage mixture)
, articular cartilage, and cortical bone as osteoclast
substrates. By measuring biomarkers of ECM turnover, we
investigated the effects of osteoclast-derived resorption
processes in degrading the ECMs of knee joint compart-
ments in vitro.
Methods
Isolation of bovine knee joint ECMs
Three intact bovine knees, derived from two cows, were
obtained from a local butcher. Articular cartilage was
isolated from the femoral condyles, using a biopsy punch
and a scalpel, and was immersed in liquid nitrogen to
render the cartilage metabolically inactive and prevent
endogenous protease activity. The cartilage slices were
then stored in 70% ethanol at 4 °C until use.
The femoral condyles were then cut sagittally into
slices using a Proxxon FET circular saw with a diamond-
coated blade (Proxxon, Föhren, Germany). The slices
were fixated in 70% ethanol for 10 min. The remaining
articular cartilage was removed with a scalpel to leave
mainly subchondral bone and calcified cartilage, the car-
tilage between the subchondral bone and the tidemark
[36], in our osteochondral ECM. Using a chisel and mal-
let, strips of osteochondral matrix were isolated from the
proximal surface of the denuded slices down to 1 mm
beneath the surface. The resulting matrix strips were
immersed in liquid nitrogen and crushed into small
pieces using a tissue pulverizer, thereby homogenizing
the ECM and allowing for even coverage of cell culture
wells, to generate the osteochondral ECM used for cul-
ture. The osteochondral ECM was then stored in 70%
ethanol at 4 °C until use.
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Bovine femurs were fixated in 70% ethanol for several
weeks after which cortical bone biopsies were drilled from
the diaphyses. The resulting bone cylinders were cut into
70-μm-thick slices using a Minitom with a diamond cut-
off wheel (Struers, Ballerup, Denmark). The bone slices
were then stored in 70% ethanol at 4 °C until use.
Histology
Femoral condyle slices, from before and after cartilage re-
moval, were fixated in 4% formaldehyde and decalcified in
15% EDTA. The decalcified slices were infiltrated with
paraffin using a Tissue-Tek VIP 5 Jr. (Sakura Finetek,
Alphen aan den Rijn, The Netherlands), embedded in par-
affin, and cut into 5–6-μm-thick sagittal sections using a
HM 360 microtome (Microm International GmbH,
Walldorf, Germany). The sections were stained with safra-
nin O-fast green. Digital micrographs were obtained with
an Olympus DP71 digital camera mounted on a BX-60
microscope with a 4X objective using the Olympus cell-
Sens software (Olympus, Center Valley, PA, USA).
von Kossa staining
Osteochondral matrix strips were stained with von
Kossa staining to verify the presence of calcified ECM.
Cortical bone slices were used as positive controls of cal-
cification and decalcified osteochondral strips and cor-
tical bone slices were used as negative controls. The
tissues were washed in type I ultrapure water and then
stained by incubating for 5 min in 1% silver nitrate
under a lamp, 2 min in 1% pyrogallol, and 5 min in 1%
sodium thiosulfate, with washes between each step. Im-
ages were obtained using a digital camera.
Resorption assays
The resorption experiments were based on three inde-
pendent resorption assays, including a small pilot (n = 3
per condition) and two larger trials (n = 6 per condition
for each). Each trial used ECMs from one unique bovine
knee and osteoclasts from one unique set of blood
donors. Data from the different trials are shown indi-
vidually—the pilot in Additional files 1, 2 and 3: Figures
S1–S3 and the two larger trials in Additional files 4, 5
and 6: Figures S4–S6 and Figs. 2, 3 and 4, respectively—
due to minor modifications in experimental setup, such
as culture time, ECM and osteoclast origin, replicate
numbers, and the number of conditions.
Prior to plating the ECMs, the osteochondral ECM
was washed three times by centrifugation and medium
replacement, whereas the slices of cortical bone and ar-
ticular cartilage were washed with medium replacement
only. Culture wells on 96-well culture plates were filled
with 50 μl of medium followed by the addition of ECMs;
osteochondral ECM was added with a spatula, until the
bottoms of the wells were covered, and cortical bone or
articular cartilage slices were added using forceps. Ma-
ture human osteoclasts derived from CD14+ monocytes
were generated as previously described [37, 38] from the
peripheral blood of anonymized blood donors obtained
from a blood bank. The mature osteoclasts were lifted
using a trypsin/EDTA mixture and a cell scraper,
counted and seeded by adding 50 μl/well of cell
suspension resulting in final culture densities of 1.0 × 105
cells/well on articular cartilage and on osteochondral
ECM and 5.0 × 104 cells/well on the cortical bone. Two
matrix-containing wells without osteoclasts were cultured
in parallel on each plate to serve as background samples
for biomarker analyses, these samples were analyzed in
the same manner as all other samples. The plates were in-
cubated for 1 h at 37 °C and 5% CO2 after which 150 μl of
medium supplemented with various resorption inhibitors
was added. The following inhibitors and final concentra-
tions were selected based on previous research [39]: 300
nM diphyllin (V-ATPase inhibitor), 5 μM E-64 (cysteine
protease inhibitor), 10 μM GM6001 (broad-spectrum
MMP inhibitor), 5 μM E-64 and 10 μM GM6001
combined (E-64/GM6001), or dimethyl sulfoxide (DMSO)
vehicle (1:2000 in medium), all of the above from Sigma-
Aldrich (St. Louis, MO, USA). After 24 h the medium was
changed by demi-depletion, replacing 150 μl of used
medium with 150 μl of fresh medium supplemented with
inhibitors, followed by another 3–4 days of culture. At the
end of the culture 200 μl of medium was collected from
each well and stored at − 20 °C until analysis. A graphical
overview of the experimental model design can be found
in Fig. 5.
Cell culture viability analysis
After collecting the cell culture supernatants, 200 μl of
medium supplemented with inhibitors and 12.5% ala-
marBlue (Thermo Fisher Scientific, Waltham, MA,
USA) was added to the wells, resulting in a final alamar-
Blue concentration of 10%, and the cells were incubated
at 37 °C and 5% CO2 for approximately 3 h. The relative
viability of the different culture conditions was then
assessed by measuring the alamarBlue fluorescence with
excitation at 540 nm and emission at 590 nm using a
SpectraMax M5 plate reader (Molecular Devices, Sunny-
vale, CA, USA). Medim from wells containing only
matrix and medium were used as background samples
(data not shown).
TRAP activity analysis
Tartrate-resistant acid phosphatase (TRAP) activity was
assessed as a measurement of relative osteoclast num-
bers in the cell cultures. 2.5 μl of media from each cell
culture well was added to a 96-well plate and mixed with
17.5 μl of type I ultrapure water. The samples were incu-
bated with 80 μl of freshly made reaction buffer (0.25 M
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acetic acid, 0.125% Triton X-100, 0.25 M NaCl, 2.5 mM
EDTA, 1.1 mg/ml of ascorbic acid, 5.75 mg/ml of diso-
dium tartrate, 2.25 mg/ml of 4-nitrophenylphosphate,
pH 5.5). The reaction mixture was incubated at 37 °C
for 1 h in the dark and was stopped by adding 100 μl of
0.3 M NaOH. Absorbance was measured at 405 nm with
650 nm as a reference using a SpectraMax M5 plate
reader (Molecular Devices, Sunnyvale, CA). Media from
wells containing only matrix and medium were used as
background samples (Additional file 7: Figure S7).
Biomarker measurements
Calcium release was analyzed by measuring the concen-
tration of total calcium (Ca2+) in medium after
resorption using a colorimetric calcium assay, based on
the o-cresolphthalein complexone (CPC) method, on an
ADVIA 1800 Clinical Chemistry System (both from
Siemens Healthineers, Erlangen, Germany). C-terminal
type I collagen fragments (CTX-I) released from re-
sorbed bone were measured using the CrossLaps for
Culture ELISA (IDS, The Boldons, UK), which was used
according to the manufacturer’s instructions. C2M, a
metabolite of MMP-mediated collagen type II degrad-
ation, was measured as previously described [40]. Bio-
marker levels below the detection limits of the
respective assays were assigned the detection limit as
their value. Medium from wells containing only matrix
and medium were used as background samples in all
biomarker measurements (Additional file 7: Figure S7).
Statistical analysis
For statistical analysis, the measured background sam-
ples from matrix without osteoclasts were subtracted
from all osteoclast-containing samples. The background-
subtracted data were normalized to the mean of the ve-
hicle condition on the respective ECM and are presented
as percentages of the vehicle. All graphs except
Additional file 7: Figure S7 contain background-
subtracted and vehicle-normalized data. The raw data
on osteoclast-derived biomarkers levels compared to
background samples (Additional file 7: Figure S7) were
not statistically analyzed. All statistical comparisons
were made within the same cell culture trial using all the
conditions’ technical replicates. These comparisons were
performed using IBM SPSS Statistics v24.0.0.0 64-bit
edition for Windows (IBM, Armonk, NY, USA). The
data were analyzed with one-way analysis of variance
(ANOVA), with the assumption that the data were nor-
mally distributed, followed by either Tukey or Dunnett’s
T3 (DT3) post hoc test depending on whether or not
equal variances could be assumed based on Levene’s test.
The post hoc test used for each test is specified in every
graph that was statistically analyzed and when p values
are given in the “Results” section (presented as pTukey or
pDT3). Statistical significance was considered to be p < 0.
05. Significance levels are reported with symbols in the
figures (*comparisons to vehicle and #comparisons to E-
64/GM6001, the latter only being shown for E-64 and
GM6001 to assess synergistic effects), where *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 and #p < 0.05, ##p <
0.01, ###p < 0.001, ####p < 0.0001. Graphs were plotted in
GraphPad Prism v7.01 for Windows (GraphPad
Software, La Jolla, CA, USA) and represent group means
and their respective standard error of the mean (SEM);
significance levels were inserted manually.
Results
Osteochondral ECM characterization and model
optimization
The osteochondral ECM was characterized by assessing
the presence of calcified cartilage interspersed with sub-
chondral bone, by safranin O-fast green staining of
femoral condyle slices, and the overall calcification of
the osteochondral matrix, by von Kossa staining of non-
crushed strips of osteochondral matrix. Prior to remov-
ing the remaining articular cartilage from the partially
denuded femoral condyles, the subchondral bone was
still covered by some articular cartilage (Fig. 1a, stained
red). No detectable articular cartilage remained above
the subchondral bone plate after denuding, but calcified
cartilage was still present interspersed with the subchon-
dral bone (Fig. 1b, stained red). The amount of bone and
cartilage in the slices varied throughout the matrix but
we do not know to what extent. The von Kossa staining
verifies the calcification of the osteochondral matrix
(Fig. 1c, center), as can be seen by comparing this matrix
strip with a decalcified matrix strip (Fig. 1d, center),
cortical bone slices (Fig. 1c–d, left), and decalcified cor-
tical bone (Fig. 1c–d, right) slices. The calcified osteo-
chondral matrix was intermittently covered by a thin
layer of cartilage that did not stain black (Fig. 1c, center)
, which was likely non-calcified articular cartilage.
To verify that osteoclast-derived biomarker release
could be generated from all ECMs, background samples
containing only medium and ECM was measured and
compared to medium from the osteoclast-containing
vehicle condition. The data clearly show that the
addition of osteoclasts resulted in increased biomarker
levels, with the exception of articular cartilage Ca2+,
CTX-I, and cortical bone C2M, compared to back-
ground levels (Additional file 7: Figure S7).
To test if the crushing procedure would affect
osteoclast-derived biomarker results, both cortical bone
and articular cartilage were metabolically inactivated,
crushed in the same manner as osteochondral ECM, and
used in resorption assays. The overall effects of the dif-
ferent resorption inhibitors on osteoclast-derived bio-
marker release from crushed ECMs did not differ from
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sliced ECMs (data not shown) and only slices of
cortical bone and articular cartilage were used in the
optimized model.
Osteoclast effects on the cortical bone compartment
The resorption of cortical bone and the biomarkers re-
leased have been extensively described before [39]. In
this study, the resorption of cortical bone in the pres-
ence of resorption inhibitors—the cysteine protease
inhibitor E-64, the MMP inhibitor GM6001, and the V-
ATPase inhibitor diphyllin—serve mainly as validation of
functional resorption on the cortical bone slices and as a
reference for the subchondral bone resorption in osteo-
chondral ECM. For the purposes of comparing protease
contribution to the different biomarker levels, the back-
ground levels were subtracted from all biomarker mea-
surements in osteoclast-containing wells followed by
normalization to the vehicle condition. Throughout this
study, the cortical bone resorption parameters performed
as expected (Fig. 2, Additional files 1 and 2: Figures S1
and S2). Ca2+ release was reduced by diphyllin (42% of
vehicle, pTukey <0.0001) whereas protease inhibitors only
had modest, albeit statistically significant, effects (Fig. 2a).
Release of the bone resorption biomarker CTX-I was sig-
nificantly reduced by all inhibitors (Fig. 2b), especially by
diphyllin (4% of vehicle, pDT3 <0.0001) which emphasizes
that the cortical bone is heavily calcified. Diphyllin in-
creased the viability (Fig. 2c) and TRAP activity (Fig. 2d)
of the cultures, as expected based on previous research
[41]. C2M—a metabolite of MMP-mediated collagen type
II degradation—release was not detectable above back-
ground levels (Additional file 7: Figure S7) indicating that
collagen type II was not present in the matrix and was not
being resorbed, nor was there any detectable cross-
reactivity with resorbed collagen type I.
Osteoclast effects on the articular cartilage compartment
Cartilage degradation by osteoclasts was assessed by the
release of C2M. There was a trend towards GM6001
completely abrogating the C2M release (0% of vehicle,
pDT3 = 0.16) and E-64 reducing it to a lesser extent (69%
of vehicle, pDT3 = 0.98), although neither was statistically
significant (Fig. 3a). The effects of E-64 varied between
trials (Additional files 3 and 4: Figures S3A and S4A).
The diphyllin condition showed a trend towards in-
creased C2M release (236% of vehicle, pDT3 = 0.79),
although some data points were outside the general pat-
tern and possibly skewed the results (Fig. 3a). This effect
also varied between trials (Additional files 3 and 4:
Figures S3A and S4A). There were no statistically signifi-
cant effects of any inhibitor on culture viability (Fig. 3b)
or osteoclast numbers (Fig. 3c). CTX-I release was not
detectable above background levels (Additional file 7:
Figure S7) indicating that collagen type I was not present
in the matrix and was not being resorbed, nor was there
any detectable cross-reactivity with resorbed collagen type
II. Similarly, Ca2+ release was not detectable above
background levels (Additional file 7: Figure S7) indicating
Fig. 1 Characterization of osteochondral extracellular matrix (ECM). Femoral condyles used to isolate the subchondral matrix were stained with
safranin O-fast green to verify the removal of the articular cartilage and the presence of calcified cartilage interspersed with the subchondral bone
(a–b). The digital micrographs represent the status of the cartilage before (a) and after articular cartilage removal (b). Isolated osteochondral ECM
strips were stained for the presence of mineralized ECM using von Kossa staining (c–d). The osteochondral strip in c (center) was un-treated
whereas the osteochondral strip in d (center) was decalcified prior to staining. Both strips are displayed next to cortical bone slices (c–d, left) and
decalcified cortical bone slices (c–d, right), serving as references of calcified matrix. Scale bars represent 1 mm (a–b) and 6 mm (c–d)
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that the cartilage was not calcified. 342FFGV-G2, a
metabolite of MMP-mediated aggrecan degradation [42],
and 374ARGS-G2, a metabolite of aggrecanase-mediated
aggrecan degradation [42], were also measured but neither
neo-epitope could be detected (data not shown).
Osteoclast effects on the osteochondral junction
compartment
In the osteochondral ECM we obtained resorption of
both bone and cartilage components. Interestingly, the
release of CTX-I (Fig. 4b) was significantly inhibited in
the presence of diphyllin (50% of vehicle, pDT3 = 0.014),
E-64 (19% of vehicle, pDT3 = 0.0008), GM6001 (51% of
vehicle, pDT3 = 0.013), and E-64/GM6001 (4% of vehicle,
pDT3 = 0.0007) whereas Ca
2+ release was not reduced by
any inhibitor (Fig. 4a), despite using well-validated dos-
ages of the inhibitors [39]. Although there was a trend
towards E-64/GM6001 reducing CTX-I more than E-64
alone (Fig. 4b) it was not statistically significant (pDT3 =
0.07); E-64/GM6001 was, however, more potent than
GM6001 alone (pDT3 = 0.007). C2M release (Fig. 4c) was
reduced by GM6001 (14% of vehicle, pDT3 = 0.006) and
to a lesser extent by E-64, which was not statistically sig-
nificant (49% of vehicle, pDT3 = 0.07), with total abroga-
tion of C2M release when combined (0% of vehicle,
pDT3 = 0.004). E-64/GM6001 was significantly different
from E-64 alone (pDT3 <0.0001) but not from GM6001
(pDT3 = 0.07). The effects of E-64 alone on C2M in other
trials were either smaller (78% of vehicle, Additional file
5: Figure S5C) or not present (128% of vehicle,
Additional file 6: Figure S6C); neither was significant
(pDT3 = 0.98 and pTukey = 0.37, respectively). Diphyllin
had a trend towards a small increase in C2M levels (Fig.
4c) but this was non-significant (122% of vehicle, pDT3 =
0.90) and was not present in other trials (Additional files
5 and 6: Figures S5C and S6C). There were no detect-
able effects on cell viability by any inhibitor (Fig. 4d).
The TRAP activity (Fig. 4e) increased in the diphyllin
condition on osteochondral ECM (154% of vehicle, pDT3
= 0.013). While E-64 and GM6001 did not affect TRAP
activity significantly (76% of vehicle, pDT3 = 0.18 and
91% of vehicle, pDT3 = 0.94), E-64/GM6001 reduced it to
65% of vehicle (pDT3 = 0.04). Similar, but non-
significant, trends were seen on cortical bone (Fig. 2d)
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Fig. 2 Resorption biomarkers released from osteoclasts cultured on cortical bone. Osteoclasts were cultured on bovine femoral cortical bone in
the presence or absence of resorption inhibitors. Resorption of calcified extracellular matrix and collagen type I was assessed by measuring the
Ca2+ (a) and C-terminal type I collagen (CTX-I) (b) concentrations, respectively, in the medium. Cell viability was assessed using alamarBlue (c) and
tartrate-resistant acid phosphatase (TRAP) activity in the medium was measured for relative osteoclast quantification (d). Data are presented as
percent of vehicle with error bars representing the SEM. Statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 for
comparisons against the vehicle and #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 for comparisons against E-64/GM6001 (only shown for E-64
and GM6001); the post hoc test used is indicated in the top left corner of each graph
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and articular cartilage (Fig. 3c). 342FFGV-G2 and
374ARGS-G2 were also measured but neither neo-
epitope was detected (data not shown).
Discussion
Inhibition of osteoclast function using bisphosphonates
has underscored a potential role of targeting osteoclasts
as a treatment for OA [43]. However, how osteoclasts
directly affect different joint compartments in OA, ex-
cept through resorption of bone, is not clear. So far clin-
ical OA trials, in general and those inhibiting bone
resorption, have failed due to lack of structural efficacy
[43]. Novel approaches are needed to determine the con-
tribution of osteoclast-derived enzymes and acidification
in degrading ECMs other than bone to improve
osteoclast-related structural efficacy in OA treatments.
In the light of this, we conducted a study focused on
osteoclast resorption mechanisms, ECM interactions
and the development of a novel tool for early drug and
biomarker validation.
To our knowledge no studies have previously quantified
the processes degrading articular cartilage and osteochon-
dral junction joint compartments in a setting where osteo-
clasts are the known and only source of degradation. In
this study, we demonstrated how osteoclasts are involved
in degrading these joint compartments and characterized
these processes using a combination of resorption inhibi-
tors and tissue-specific biomarkers. In brief, our study
supports osteoclast-derived cathepsin K-mediated and
MMP-mediated resorption of calcified cartilage and
articular cartilage independently of acidification, as
measured by the C2M neo-epitope. A graphical overview
of the experimental model design and the osteoclast-
derived resorption processes that contributed to the ECM
degradation biomarkers measured in our study can be
found in Fig. 5. Using this novel cell model, we were able
to investigate the role of osteoclast-derived enzymes and
acidification in directly degrading articular cartilage and
osteochondral junction compartments.
Osteoclasts generated inhibitable Ca2+ release from
cortical bone but not from the osteochondral ECM—the
V-ATPase inhibitor diphyllin had no effect on osteochon-
dral Ca2+ release—which suggests that the osteochondral
Ca2+ was not derived from resorption. Due to this
discrepancy, reference biomarker data from cortical bone
are necessary for this cell culture model to verify normal
resorption and validate each experiment. As Ca2+ was
present at equal levels in all osteochondral osteoclast
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Fig. 3 Resorption biomarkers released from osteoclasts cultured on articular cartilage. Osteoclasts were cultured on articular cartilage from bovine
femoral condyles in the presence or absence of resorption inhibitors. Resorption of collagen type II was assessed by measuring C2M concentrations in
the medium (a). Cell viability was assessed using alamarBlue (b) and tartrate-resistant acid phosphatase (TRAP) activity in the medium was measured
for relative osteoclast quantification (c). Data are presented as percent of vehicle with error bars representing the SEM. Statistical significance is
indicated by *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 for comparisons against the vehicle and #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 for
comparisons against E-64/GM6001 (only shown for E-64 and GM6001), the post hoc test used is indicated in the top left corner of each graph
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conditions, i.e. Ca2+ levels were increased by an equal
amount in all osteoclast conditions compared to
background levels, we speculate that the Ca2+ was derived
from cellular metabolism and that the osteochondral
ECM is not highly calcified like cortical bone, which
appears to be supported by the von Kossa staining.
Inhibiting Ca2+ release by targeting the V-ATPase typic-
ally raises the viability and the TRAP activity of osteoclast
cultures [41, 44], likely due to Ca2+ release from resorption
inducing osteoclast apoptosis [45]. Accordingly, TRAP
activity was raised by diphyllin to a lesser extent in the
osteochondral cultures than it was in the bone cultures,
and similarly viability was only marginally and non-
significantly raised by diphyllin in the osteochondral cul-
tures, further supporting that the calcification of the osteo-
chondral ECM was relatively low.
The osteochondral CTX-I levels also support the hy-
pothesis of low calcification as CTX-I was only moder-
ately affected by diphyllin when compared to the effects
of diphyllin on cortical bone. The apparent discrepancy
between the CTX-I and calcium analyses on osteochon-
dral ECM could however be a matter of different
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Fig. 4 Resorption biomarkers released from osteoclasts cultured on osteochondral extracellular matrix (ECM). Osteoclasts were cultured on
osteochondral ECM from bovine femoral condyles in the presence or absence of resorption inhibitors. Resorption of calcified ECM and collagen
type I was assessed by measuring the Ca2+ (a) and C-terminal type I collagen (CTX-I) (b) concentrations, respectively, in the medium. Resorption
of collagen type II was assessed by measuring C2M (c) concentrations in the medium. Cell viability was assessed using alamarBlue (d) and
tartrate-resistant acid phosphatase (TRAP) activity in the medium was measured for relative osteoclast quantification (e). Data are presented as
percent of vehicle with error bars representing the SEM. Statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 for
comparisons against the vehicle and #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 for comparisons against E-64/GM6001 (only shown for E-64
and GM6001); the post hoc test used is indicated in the top left corner of each graph
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sensitivity between the two analyses. Osteoclasts gener-
ated CTX-I from osteochondral ECM primarily through
cathepsin K-mediated processes as indicated by the in-
hibitor panel, but secondarily also through MMP-
mediated processes, in a manner similar to osteoclasts
on cortical bone. Interestingly, the MMP inhibition ap-
peared to have a stronger effect on osteochondral CTX-I
release than on cortical bone CTX-I release. Similarly,
osteoclasts cultured on decalcified bone display a stron-
ger reduction in CTX-I release when MMPs are inhib-
ited than they do on non-decalcified cortical bone,
whereas the effects of cathepsin K inhibition are blunted
on decalcified cortical bone, supporting that MMPs are
the predominant proteases on a non-calcified matrix [8].
Osteoclast-mediated cartilage degradation has previously
been demonstrated by measuring the release of glycosami-
noglycans (GAGs) from osteoclasts cultured on articular
cartilage [23]. In our study we instead demonstrated
osteoclast-derived cartilage degradation using the C2M
biomarker. C2M has previously been shown to be able to
distinguish between healthy subjects and patients or
between subsets of patients with arthritic diseases—such
as OA [40, 46], RA [47–49] and ankylosing spondylitis
[50, 51]—when measured in patient serum. Additionally,
C2M has been characterized in ex vivo models of inflam-
matory cartilage degradation where it was shown that
MMP inhibition reduces the C2M release [40]. These
studies make C2M a highly relevant biomarker for both
clinical studies of OA and for investigations of cartilage
degradation mechanisms. Using our in vitro model we
have explored additional biological mechanisms through
which the C2M biomarker can be generated. Our study
highlights how our model can be used for biomarker
discovery and validation and for drug efficacy testing in
diseases where osteoclasts may contribute to the disease
process. However, it is possible that the mechanisms gen-
erating C2M in vivo and their overall contribution to C2M
levels and disease may differ from the in vitro conditions.
The cartilage was degraded by osteoclast-derived
MMPs in our study, as the C2M neo-epitope is mainly
generated through MMP-cleavage of collagen type II
and GM6001 potently inhibited the C2M release. From
the osteochondral ECM we detected C2M release, which
could be inhibited by E-64 and GM6001. In two of the
three trials there was a trend towards cathepsin K-
mediated processes contributing to C2M release from
osteochondral ECM. The effect of E-64 was more appar-
ent when it was used in combination with GM6001. This
could indicate that cathepsin K contributes to release or
access to the neo-epitope rather than to the generation
of the neo-epitope. Cathepsin K-mediated bone resorp-
tion could also affect osteochondral C2M by enabling
access to cartilage encapsulated in bone; this in turn
could lead to variation in the efficacy of E-64 based on
the bone-to-cartilage ratio in the matrix. Cathepsin K
appeared to contribute to C2M release also on articular
cartilage in two of three trials, although E-64 did not
have a statistically significant effect on cartilage C2M re-
lease in any trial. The small effects of E-64 on cartilage
degradation could be due to the low levels of calcifica-
tion. E-64 has been shown to reduce CTX-I release from
decalcified bone less than from normally calcified bone
[8]. ECMs with low calcification presumably result in
less acidification, thereby reducing the activity of
Fig. 5 Overview of the experimental model design and results. Cortical bone, articular cartilage and an osteochondral matrix, consisting of
subchondral bone and calcified cartilage, were isolated from bovine femoral diaphyses and femoral condyles, and fixated in 70% ethanol. The
articular cartilage and the osteochondral matrix were metabolically inactivated by immersion in liquid nitrogen. The osteochondral matrix was
crushed to generate a homogeneous osteochondral extracellular matrix (ECM) for culture. Human osteoclasts derived from CD14+ monocytes
were cultured on the different matrices in the presence of vacuolar-type H+-ATPase, matrix metalloproteinase (MMP) and cathepsin K inhibitors.
The contributions of hydrochloric acid, MMPs and cathepsin K in degrading the ECMs were assessed by measuring biomarkers of ECM
degradation in the culture supernatants. CTX-I, C-terminal type I collagen
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cathepsin K as it is most effective at an acidic pH [52].
Another factor is the biomarker itself as C2M is primarily
generated by MMPs. In previous studies using a model of
inflammatory cartilage degradation, E-64 had no effect on
C2M release [40] even though cathepsin K is expressed in
this model [29]. In our study diphyllin had no inhibitory ef-
fect on cartilage C2M or osteochondral C2M, supporting
the hypothesis that both non-calcified and calcified cartilage
can be resorbed independently of acidification. This is in
line with the findings of Touaitahuata et al. that Dock5−/−
murine osteoclasts degrade hypertrophic cartilage without
acidifying the ECM due to dysfunctional sealing zones [53].
We were unable to detect the aggrecan degradation bio-
markers 342FFGV-G2 and 374ARGS-G2 from any matrix.
Although we demonstrated MMP-mediated collagen type
II degradation, the MMPs present might not generate
342FFGV-G2 or detectable amounts thereof, possibly due to
the osteoclast source and substrate affecting which MMPs
are secreted [54]. It is also possible that our matrices do not
contain enough aggrecan to generate detectable levels of
342FFGV-G2 or 374ARGS-G2. In a model of inflammatory
cartilage degradation the 374ARGS-G2 neo-epitope is
mainly generated by a disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS)-4 [55], although
ADAMTS-5 is also known to degrade aggrecan [56], but it
is not known if osteoclasts express ADAMTS-4 or 5, hence,
osteoclasts might not be able to generate 374ARGS-G2.
While a large body of evidence supports both MMPs
[6, 8, 29, 30] and cathepsin K [3, 6, 8, 31] contributing
to bone and cartilage degradation, their contribution in
degrading calcified cartilage or in degrading cartilage in
a setting where they are known to be derived from oste-
oclasts has to our knowledge not been demonstrated
previously. To date osteoclast inhibitors have yielded
mixed results in osteoarthritis clinical trials despite
promise in vivo. Hence, there is a need for elucidating
the contribution of different osteoclast-derived proteases
to ECM degradation. In addition to demonstrating how
cysteine proteases and MMPs derived from human oste-
oclasts may degrade knee joint ECMs, in this study we
also describe how these processes can be investigated
using biomarkers directly associated with the enzymatic
processing of the ECM. The in vitro model itself and the
novel use of biomarkers like C2M in assessing cartilage
resorption is also an important finding, in addition to
demonstrating calcified cartilage resorption by MMPs
and cathepsins in an acidification-independent manner.
Our novel model holds potential for further studies in
the early development of novel drugs and biomarkers fo-
cused on knee joint ECM remodeling.
Previous studies have suggested that the ECM is an
important regulator of the osteoclast phenotype [28].
For the purposes of our study it is unclear if the relative
importance of the osteoclast processes required for
generating a particular biomarker was related to ECM-
dependent phenotype shifts or different osteoclast sub-
types. Our data do however demonstrate that osteoclast
functionality is highly dependent on what matrix they
are resorbing, as previously suggested [8, 28, 39, 57],
since the different matrices required different osteoclast
proteases and amounts of acidification for degradation.
A previous study showed that monocytes from patients
with OA display increased osteoclastogenesis accompan-
ied by increased bone resorption and reduced apoptosis
in vitro [22]. These findings suggest a phenotype shift in
OA osteoclasts, thus it may be of interest to investigate
if these osteoclasts also display increased cartilage or
calcified cartilage resorption with an altered biomarker
profile in future studies using our model.
Our cell culture model comes with some limitations.
The amount of matrix obtained from a single knee and
the large number of osteoclasts required to perform the
cultures with a suitable number of technical replicates
limits the number of conditions that can be used, resulting
in relatively low statistical power that is sensitive to vari-
ation within conditions. Increased robustness could be
achieved by investigating only the matrix and compound
of interest in addition to reference matrices (cortical bone
and/or articular cartilage) and reference inhibitors (diphyl-
lin, E-64, and GM6001); this was, however, not suitable
for the profiling approach of our study. Some experimen-
tal outputs varied between experiments, as can be seen by
comparing the data in this article (Figs. 2, 3 and 4) with
the supplementary data (Additional files 1, 2, 3, 4, 5 and 6:
Figures S1–S6). This could potentially be explained by dif-
ferences in osteoclast quality between donors and varia-
tions in matrix content between the knee joints, further
necessitating strict use of reference matrices and inhibi-
tors to validate each experiment. Finally, due to the in
vitro design of our study, the findings cannot be directly
extrapolated to the OA disease process.
In our study we decided to use a molecular in vitro ap-
proach to investigate the role of osteoclasts in degrading
the knee joint ECMs rather than an in vivo approach.
Considering that the contribution of osteoclasts or the
different ECMs to the biomarker release cannot be pre-
cisely determined in vivo, an in vitro study provides a
clearer picture of the osteoclast-derived mechanisms in-
volved in resorbing the different ECMs. Additionally, the
inter-species phenotype differences observed between
human and murine osteoclasts with deficits in e.g.
cathepsins (or with inhibited cathepsins) [58–60] indi-
cate that the use of non-human osteoclasts are unlikely
to be an accurate representation of the human situation.
The use of bisphosphonates in clinical OA trials have
yielded mixed results, despite great promise in vivo, and
therefore investigations of how human osteoclasts may
contribute to the degradation of knee joint ECMs is of
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importance—something which, to our knowledge, has
not been previously investigated in articular cartilage
and osteochondral junction joint compartments.
Conclusions
In conclusion, in this study we have developed a novel cell
culture model to demonstrate the osteoclasts’ capability of
degrading the osteochondral junction and articular cartilage
joint compartments in a manner that can be assessed using
tissue-specific and protease-specific biomarkers. Our study
supports that osteoclasts can resorb cartilage and calcified
cartilage independently of acidification. We demonstrated
both MMP-mediated and cysteine protease-mediated re-
sorption of calcified cartilage. The osteoclast functionality
was highly dependent on the resorbed substrate, as differ-
ent ECMs required different osteoclast processes for
degradation. Our novel culture system has potential to
facilitate drug and biomarker development for rheumatic
diseases, e.g. osteoarthritis, with pathological osteoclast pro-
cesses in specific joint compartments.
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Additional file 1: Figure S1. Resorption biomarkers released from
osteoclasts cultured on cortical bone in an additional trial. Osteoclasts
were cultured on bovine femoral cortical bone in the presence or
absence of resorption inhibitors. Resorption of calcified ECM and collagen
type I was assessed by measuring the Ca2+ (A) and CTX-I (B) concentrations,
respectively, in the medium. Cell viability was assessed using alamarBlue (C)
and TRAP activity in the medium was measured for relative osteoclast
quantification (D). Data are presented as percent of vehicle with error bars
representing the SEM. Statistical significance is indicated by *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001 for comparisons against the vehicle and #p
< 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 for comparisons against E-64/
GM6001 (only shown for E-64 and GM6001); the post hoc test used is
indicated in the top left corner of each graph. (PDF 32 kb)
Additional file 2: Figure S2. Resorption biomarkers released from
osteoclasts cultured on cortical bone in pilot trial. Osteoclasts were cultured
on bovine femoral cortical bone in the presence or absence of resorption
inhibitors. Resorption of calcified ECM and collagen type I was assessed by
measuring the Ca2+ (A) and CTX-I (B) concentrations, respectively, in the
medium. TRAP activity in the medium was measured for relative osteoclast
quantification (C). Data are presented as percent of vehicle with error bars
representing the SEM. Statistical significance is indicated by *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001 for comparisons against the vehicle; the post
hoc test used is indicated in the top left corner of each graph. (PDF 28 kb)
Additional file 3: Figure S3. Resorption biomarkers released from
osteoclasts cultured on articular cartilage in an additional trial. Osteoclasts were
cultured on articular cartilage from bovine femoral condyles in the presence or
absence of resorption inhibitors. Resorption of collagen type II was assessed by
measuring C2M (A) concentrations in the medium. Cell viability was assessed
using alamarBlue (B) and TRAP activity in the medium was measured for
relative osteoclast quantification (C). Data are presented as percent of vehicle
with error bars representing the SEM. Statistical significance is indicated by *p
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 for comparisons against the
vehicle and #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 for comparisons
against E-64/GM6001 (only shown for E-64 and GM6001); the post hoc test
used is indicated in the top left corner of each graph. (PDF 30 kb)
Additional file 4: Figure S4. Resorption biomarkers released from
osteoclasts cultured on articular cartilage in the pilot trial. Osteoclasts
were cultured on articular cartilage from bovine femoral condyles in the
presence or absence of resorption inhibitors. Resorption of collagen type II
was assessed by measuring C2M (A) concentrations in the medium. TRAP
activity in the medium was measured for relative osteoclast quantification
(B). Data are presented as percent of vehicle with error bars representing
the SEM. Statistical significance is indicated by *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001 for comparisons against the vehicle; the post hoc test
used is indicated in the top left corner of each graph. (PDF 27 kb)
Additional file 5: Figure S5. Resorption biomarkers released from
osteoclasts cultured on osteochondral ECM in an additional trial.
Osteoclasts were cultured on osteochondral ECM from bovine femoral
condyles in the presence or absence of resorption inhibitors. Resorption
of calcified ECM and collagen type I was assessed by measuring the Ca2+
(A) and CTX-I (B) concentrations, respectively, in the medium. Resorption
of collagen type II was assessed by measuring C2M (C) concentrations in
the medium. Cell viability was assessed using alamarBlue (D) and TRAP
activity in the medium was measured for relative osteoclast quantification
(E). Data are presented as percent of vehicle with error bars representing
the SEM. Statistical significance is indicated by *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001 for comparisons against the vehicle and #p < 0.05,
##p < 0.01, ###p < 0.001, ####p < 0.0001 for comparisons against E-64/
GM6001 (only shown for E-64 and GM6001); the post hoc test used is
indicated in the top left corner of each graph. (PDF 33 kb)
Additional file 6: Figure S6. Resorption biomarkers released from
osteoclasts cultured on osteochondral ECM in the pilot trial. Osteoclasts
were cultured on osteochondral ECM from bovine femoral condyles in
the presence or absence of resorption inhibitors. Resorption of calcified
ECM and collagen type I was assessed by measuring the Ca2+ (A) and
CTX-I (B) concentrations, respectively, in the medium. TRAP activity data
could not be generated in these samples. Resorption of collagen type II
was assessed by measuring C2M (C) concentrations in the medium. Data
are presented as percent of vehicle with error bars representing the SEM.
Statistical significance is indicated by *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 for comparisons against the vehicle; the post hoc test used
is indicated in the top left corner of each graph. (PDF 27 kb)
Additional file 7: Figure S7. Osteoclast-derived biomarker levels
compared to background levels. Biomarkers were measured in medium
from wells containing only matrix (Background, white) or matrix and
osteoclasts (Osteoclasts, black), cultured on bovine femoral cortical bone
(Bone), articular cartilage (Cartilage) or osteochondral ECM (Osteoch.).
Resorption of calcified ECM and collagen type I was assessed by measuring
the Ca2+ (A) and CTX-I (B) concentrations, respectively, in the medium. Re-
sorption of collagen type II was assessed by measuring C2M (C) concentra-
tions in the medium. TRAP activity in the medium was measured for relative
osteoclast quantification (D). Data from one representative resorption assay
are presented as the mean of the measured parameters in background wells
or osteoclast-containing wells. Error bars represent the SEM. (PDF 32 kb)
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